BARTELS, STEPHEN P.,史缇芬P 巴特尔斯,史緹芬P 巴特爾斯,史缇芬P 巴特尔斯,史緹芬P 巴特爾斯
申请号:
TW097135854
公开号:
TWI366462B
申请日:
2008.09.18
申请国别(地区):
TW
年份:
2012
代理人:
摘要:
A composition for controlling or preventing progression of glaucoma comprises a material that reduces or inhibits production of a TGF-beta isoform or a chemokine or cytokine that stimulates expression of a TGF-beta isoform. The material can comprise a dissociated glucocorticoid receptor agonist ("DIGRA"), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can further comprise an antagonist to TGF-beta. It is administered to a patient who has undergone glaucoma filtration surgery to ensure a functioning filtering bleb following such surgery.一種控制或預防青光眼進展之組合物,係包含會降低或抑制TGF-β異構重組物或化學細胞活素或細胞活素(會刺激TGF-β異構重組物之表現)生產之物質。該物質可包括經解離之類皮質糖受體催動劑("DIGRA"),其前體藥物,其藥學上可接受之鹽或其藥學上可接受之酯。該組合物可進一步包含對TGF-β之拮抗劑。其係被投予已進行青光眼濾過手術之病患,以確保在此種手術後之發揮功能濾過水疱。